Cargando…

Induction of cross-reactive, mucosal anti-SARS-CoV-2 antibody responses in rheumatoid arthritis patients after 3rd dose of COVID-19 vaccination

Systemic vaccination against SARS-CoV-2 elicited high titers of specific antibodies in the blood and in the oral cavity. Preexisting autoimmune diseases, such as rheumatoid arthritis, and biological treatments, like B cell depletion, are known to exhibit higher risk of severe COVID-19 manifestation...

Descripción completa

Detalles Bibliográficos
Autores principales: Bondareva, M., Letz, P., Karberg, K., Schrezenmeier, E., Semin, I., Rincon-Arevalo, H., Dörner, T., Mashreghi, M.F., Stefanski, A.-L., Kruglov, A.A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9550527/
https://www.ncbi.nlm.nih.gov/pubmed/36228431
http://dx.doi.org/10.1016/j.jaut.2022.102918
_version_ 1784805907859767296
author Bondareva, M.
Letz, P.
Karberg, K.
Schrezenmeier, E.
Semin, I.
Rincon-Arevalo, H.
Dörner, T.
Mashreghi, M.F.
Stefanski, A.-L.
Kruglov, A.A.
author_facet Bondareva, M.
Letz, P.
Karberg, K.
Schrezenmeier, E.
Semin, I.
Rincon-Arevalo, H.
Dörner, T.
Mashreghi, M.F.
Stefanski, A.-L.
Kruglov, A.A.
author_sort Bondareva, M.
collection PubMed
description Systemic vaccination against SARS-CoV-2 elicited high titers of specific antibodies in the blood and in the oral cavity. Preexisting autoimmune diseases, such as rheumatoid arthritis, and biological treatments, like B cell depletion, are known to exhibit higher risk of severe COVID-19 manifestation and increased frequency of breakthrough infections after vaccination. We hypothesized that such increased risk is associated with an aberrant induction of secreted antibodies in the oral cavity. Here we evaluated the levels of secreted antibodies in the oral cavity against the SARS-CoV-2 Spike protein during the course of vaccination in RA patients with or without B cell depletion. We found that total salivary IgG levels were correlated with number of B cells in the blood. Anti-Spike IgG responses 7 days after second vaccination were induced in the oral cavity of all healthy individuals, while only 6 out 23 RA patients exhibited anti-Spike IgG in their saliva regardless of B cell depleting therapy. Importantly, both salivary and serologic anti-Spike IgG and IgA responses towards WT and omicron Spike variants were efficiently induced by third vaccination in RA patients with or without B cell depletion to the levels that were similar to healthy individuals. Altogether, these data advocate for the necessity of three dose vaccination for RA patients to mount anti-Spike antibody responses at the mucosal surfaces and annotate the reduction of secreted salivary IgG by B cell depletion.
format Online
Article
Text
id pubmed-9550527
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-95505272022-10-11 Induction of cross-reactive, mucosal anti-SARS-CoV-2 antibody responses in rheumatoid arthritis patients after 3rd dose of COVID-19 vaccination Bondareva, M. Letz, P. Karberg, K. Schrezenmeier, E. Semin, I. Rincon-Arevalo, H. Dörner, T. Mashreghi, M.F. Stefanski, A.-L. Kruglov, A.A. J Autoimmun Article Systemic vaccination against SARS-CoV-2 elicited high titers of specific antibodies in the blood and in the oral cavity. Preexisting autoimmune diseases, such as rheumatoid arthritis, and biological treatments, like B cell depletion, are known to exhibit higher risk of severe COVID-19 manifestation and increased frequency of breakthrough infections after vaccination. We hypothesized that such increased risk is associated with an aberrant induction of secreted antibodies in the oral cavity. Here we evaluated the levels of secreted antibodies in the oral cavity against the SARS-CoV-2 Spike protein during the course of vaccination in RA patients with or without B cell depletion. We found that total salivary IgG levels were correlated with number of B cells in the blood. Anti-Spike IgG responses 7 days after second vaccination were induced in the oral cavity of all healthy individuals, while only 6 out 23 RA patients exhibited anti-Spike IgG in their saliva regardless of B cell depleting therapy. Importantly, both salivary and serologic anti-Spike IgG and IgA responses towards WT and omicron Spike variants were efficiently induced by third vaccination in RA patients with or without B cell depletion to the levels that were similar to healthy individuals. Altogether, these data advocate for the necessity of three dose vaccination for RA patients to mount anti-Spike antibody responses at the mucosal surfaces and annotate the reduction of secreted salivary IgG by B cell depletion. Elsevier Ltd. 2022-12 2022-10-11 /pmc/articles/PMC9550527/ /pubmed/36228431 http://dx.doi.org/10.1016/j.jaut.2022.102918 Text en © 2022 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Bondareva, M.
Letz, P.
Karberg, K.
Schrezenmeier, E.
Semin, I.
Rincon-Arevalo, H.
Dörner, T.
Mashreghi, M.F.
Stefanski, A.-L.
Kruglov, A.A.
Induction of cross-reactive, mucosal anti-SARS-CoV-2 antibody responses in rheumatoid arthritis patients after 3rd dose of COVID-19 vaccination
title Induction of cross-reactive, mucosal anti-SARS-CoV-2 antibody responses in rheumatoid arthritis patients after 3rd dose of COVID-19 vaccination
title_full Induction of cross-reactive, mucosal anti-SARS-CoV-2 antibody responses in rheumatoid arthritis patients after 3rd dose of COVID-19 vaccination
title_fullStr Induction of cross-reactive, mucosal anti-SARS-CoV-2 antibody responses in rheumatoid arthritis patients after 3rd dose of COVID-19 vaccination
title_full_unstemmed Induction of cross-reactive, mucosal anti-SARS-CoV-2 antibody responses in rheumatoid arthritis patients after 3rd dose of COVID-19 vaccination
title_short Induction of cross-reactive, mucosal anti-SARS-CoV-2 antibody responses in rheumatoid arthritis patients after 3rd dose of COVID-19 vaccination
title_sort induction of cross-reactive, mucosal anti-sars-cov-2 antibody responses in rheumatoid arthritis patients after 3rd dose of covid-19 vaccination
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9550527/
https://www.ncbi.nlm.nih.gov/pubmed/36228431
http://dx.doi.org/10.1016/j.jaut.2022.102918
work_keys_str_mv AT bondarevam inductionofcrossreactivemucosalantisarscov2antibodyresponsesinrheumatoidarthritispatientsafter3rddoseofcovid19vaccination
AT letzp inductionofcrossreactivemucosalantisarscov2antibodyresponsesinrheumatoidarthritispatientsafter3rddoseofcovid19vaccination
AT karbergk inductionofcrossreactivemucosalantisarscov2antibodyresponsesinrheumatoidarthritispatientsafter3rddoseofcovid19vaccination
AT schrezenmeiere inductionofcrossreactivemucosalantisarscov2antibodyresponsesinrheumatoidarthritispatientsafter3rddoseofcovid19vaccination
AT semini inductionofcrossreactivemucosalantisarscov2antibodyresponsesinrheumatoidarthritispatientsafter3rddoseofcovid19vaccination
AT rinconarevaloh inductionofcrossreactivemucosalantisarscov2antibodyresponsesinrheumatoidarthritispatientsafter3rddoseofcovid19vaccination
AT dornert inductionofcrossreactivemucosalantisarscov2antibodyresponsesinrheumatoidarthritispatientsafter3rddoseofcovid19vaccination
AT mashreghimf inductionofcrossreactivemucosalantisarscov2antibodyresponsesinrheumatoidarthritispatientsafter3rddoseofcovid19vaccination
AT stefanskial inductionofcrossreactivemucosalantisarscov2antibodyresponsesinrheumatoidarthritispatientsafter3rddoseofcovid19vaccination
AT kruglovaa inductionofcrossreactivemucosalantisarscov2antibodyresponsesinrheumatoidarthritispatientsafter3rddoseofcovid19vaccination